NASDAQ:ENTAEnanta Pharmaceuticals Stock Price, Forecast & News

Enanta Pharmaceuticals' stock was trading at $52.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ENTA shares have decreased by 2.5% and is now trading at $51.60. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Enanta Pharmaceuticals.

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Enanta Pharmaceuticals.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) posted its earnings results on Wednesday, May, 6th. The biotechnology company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.73) by $0.43. The biotechnology company earned $27.60 million during the quarter, compared to analysts' expectations of $29.16 million. Enanta Pharmaceuticals had a return on equity of 5.04% and a net margin of 13.46%. Enanta Pharmaceuticals's quarterly revenue was down 30.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.20 earnings per share. View Enanta Pharmaceuticals' earnings history.

6 brokers have issued twelve-month price targets for Enanta Pharmaceuticals' stock. Their forecasts range from $49.00 to $130.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $71.60 in the next twelve months. This suggests a possible upside of 38.8% from the stock's current price. View analysts' price targets for Enanta Pharmaceuticals.

Press coverage about ENTA stock has trended positive on Thursday, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Enanta Pharmaceuticals earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an impact on the stock's share price in the near term. View the latest news aboutEnanta Pharmaceuticals.

Enanta Pharmaceuticals saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 1,600,000 shares, a decrease of 8.6% from the April 30th total of 1,750,000 shares. Based on an average daily trading volume, of 225,700 shares, the short-interest ratio is currently 7.1 days. Currently, 9.1% of the shares of the company are short sold. View Enanta Pharmaceuticals' Current Options Chain.

Some companies that are related to Enanta Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), PPD (SDGR), Global Blood Therapeutics (GBT), GW Pharmaceuticals PLC- (GWPH), Nektar Therapeutics (NKTR), Zai Lab (ZLAB), Evotec (EVTCY), ChemoCentryx (CCXI), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), Allakos (ALLK), Biohaven Pharmaceutical (BHVN), Arrowhead Pharmaceuticals (ARWR) and Deciphera Pharmaceuticals (DCPH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), Gilead Sciences (GILD), AbbVie (ABBV), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), GW Pharmaceuticals PLC- (GWPH) and Netflix (NFLX).

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

Enanta Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.21%), State Street Corp (4.56%), Krensavage Asset Management LLC (3.50%), First Manhattan Co. (2.07%), Acadian Asset Management LLC (1.73%) and Deutsche Bank AG (1.32%). Company insiders that own Enanta Pharmaceuticals stock include Bruce L A Carter, George Golumbeski, Jay R Luly, Nathalie Adda, Nathaniel S Gardiner, Paul J Mellett, Tim Ocain and Yat Sun Or. View institutional ownership trends for Enanta Pharmaceuticals.

ENTA stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Invesco Ltd., First Manhattan Co., AJO LP, AQR Capital Management LLC, Two Sigma Investments LP, and Nuveen Asset Management LLC. View insider buying and selling activity for Enanta Pharmaceuticals.

ENTA stock was bought by a variety of institutional investors in the last quarter, including Krensavage Asset Management LLC, Deutsche Bank AG, Grantham Mayo Van Otterloo & Co. LLC, State Street Corp, International Biotechnology Trust PLC, Aviva PLC, Two Sigma Advisers LP, and BNP Paribas Arbitrage SA. View insider buying and selling activity for Enanta Pharmaceuticals.

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ENTA stock can currently be purchased for approximately $51.60.

Enanta Pharmaceuticals has a market capitalization of $1.03 billion and generates $205.20 million in revenue each year. The biotechnology company earns $46.38 million in net income (profit) each year or $2.21 on an earnings per share basis. Enanta Pharmaceuticals employs 113 workers across the globe.

The official website for Enanta Pharmaceuticals is www.enanta.com.

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]